{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-015247","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2024-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.585690+00:00","generated_at":"2026-06-04T01:16:19.029975+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cardiff Oncology AACR data: onvansertib shows 73% ORR in bev-naive RAS-mutated mCRC vs 19% in bev-exposed","bullets":["Bev-naive patients in Phase 1b/2 trial had ORR of 73% vs 19% for bev-exposed; odds ratio 13.64 (p<0.001) and PFS HR 0.21 (p=0.003).","Onvansertib inhibits hypoxia pathway via HIF1α regulation, reducing tumor vascularization; combo with bevacizumab enhances reduction.","In RAS WT mCRC PDX models, onvansertib as monotherapy induced stasis/regression in 70% (14/20) of models; combo with cetuximab in 90% (18/20).","In SCLC cisplatin-resistant PDX models, onvansertib + paclitaxel led to tumor regression lasting 2 months post-treatment.","CRDF-004 Phase 2 trial in first-line RAS-mutated mCRC to randomize 90 patients to onvansertib 20mg or 30mg plus SoC vs SoC alone."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-015247","json":"https://secwatch.observer/filing/0001628280-24-015247.json","markdown":"https://secwatch.observer/filing/0001628280-24-015247.md","text":"https://secwatch.observer/filing/0001628280-24-015247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828024015247/0001628280-24-015247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828024015247/crdf-20240408.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:16:19.029975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}